ANALYSIS: With an Obermatt 360° View of 75 (better than 75% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Royalty Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Royalty Pharma. The consolidated Value Rank has an attractive rank of 92, which means that the share price of Royalty Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 92% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 62, which means that professional investors are more optimistic about the stock than for 62% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 49, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 36, meaning the company has a riskier financing structure than 64 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more